Business Context and Reporting Period
This Form 8-K Current Report was filed by Diamedica Therapeutics Inc. on May 23, 2022. The report discloses the immediate resignation of Harry Alcorn, Jr., Pharm.D., who served as Senior Vice President of Clinical Operations.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change is the departure of a senior officer. Dr. Alcorn resigned effective immediately on May 23, 2022. In connection with this departure, the Company entered into a Separation Agreement and a Consulting Services Agreement.
Management Commentary, Risks, and Unusual Items
Separation Terms: Dr. Alcorn is entitled to the following benefits under the Separation Agreement:
- Salary continuation for at least nine months, potentially extending to 12 months if he does not secure full-time employment.
- Payment of COBRA continuation coverage premiums for up to nine months or until new employment is secured.
- A pro rata portion of his target annual bonus for the year of termination.
- Immediate acceleration of all outstanding options to purchase the Company's common shares.
Consulting Arrangement: Dr. Alcorn will serve as a consultant on an as-needed basis at a rate of $200 per hour. No fees will be paid while he receives salary continuation payments.
Risks and Contingencies: The agreement includes customary non-disparagement and confidentiality undertakings. The filing notes that the summary is qualified by the full text of the agreements attached as exhibits.
Investor Verification Checklist
- Verify the impact of the Senior Vice President of Clinical Operations' departure on ongoing clinical trials.
- Review the attached Separation Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for specific legal covenants.
- Assess the financial impact of the accelerated stock options and salary continuation on the Company's cash burn rate.
- Confirm the timeline for appointing a replacement for the clinical operations role.